SDF-1 restores angiogenesis synergistically with VEGF upon LDL exposure despite CXCR4 internalization and degradation

Cardiovascular Research

Volumn 100, Issue 3, 2013, Pages 481-491

  Jin, Fengyan ^a   Hagemann, Nina ^a   Schäfer, Simon T ^a   Brockmeier, Ulf ^b   Zechariah, Anil ^a   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Angiogenesis; Capillary formation; Endothelial cell; Growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; LOW DENSITY LIPOPROTEIN; MATRIGEL; OXIDIZED LOW DENSITY LIPOPROTEIN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRADATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INTERNALIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS; CAPILLARY FORMATION; ENDOTHELIAL CELL; GROWTH FACTOR;

ANGIOGENESIS INDUCING AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOCYTOSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, LDL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84887929983     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt209     Document Type: Article

References (38)

1. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascu-larity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6:127-133.
2. Henry TD, Annex BH, Mc Kendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107:1359-1365.
3. Hedman M, Hartikainen J, Syvanne M., Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial. Circulation 2003; 107:2677-2683.
4. Kukuła K, Chojnowska L, Da̧browski M, Witkowski A, Chmielak Z, Skwarek M et al. Intra-myocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 2011; 161:581-589.
5. Rajagopalan S, Mohler III ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933-1938.
6. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euro-inject One trial. J Am Coll Cardiol 2005; 45:982-988.
7. Simons M, Ware JA Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003; 2:863-871.
8. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009; 8:491-500.
9. Hermann DM, Zechariah A. Implications of vascular endothelial growth factor for post-ischemic neurovascular remodeling. J Cereb Blood Flow Metab 2009; 29:1620-1643.
10. Hermann DM, Chopp M. Promoting brain remodeling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012; 11: 369-380.
11. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD Serum cholesterol levels and six-year mortality from strokein 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904-910.
12. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002; 33:1863-1868.
13. Duan J, Murohara T, Ikeda H., Katoh A, Shintani S, Sasaki K et al. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation 2000; 102:III370-III376.
14. Matter CM, Ma L, von Lukowicz T, Meier P, Lohmann C., Zhang D et al. Increased balloon-induced inflammation, proliferation, and neointima formationin apolipoprotein E (Apo E) knockout mice. Stroke 2006; 37:2625-2632.
15. Osto E, Matter CM, Kouroedov A, Malinski T., Bachschmid M, Camici GG et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia- induced endo-thelial dysfunction and oxidative stress. Circulation 2008; 118:2073-2080.
16. Jin F, Hagemann N, Brockmeier U., Schäfer ST, Zechariah A, Hermann DM. LDL attenuates VEGF-induced angiogenesis via mechanisms involving VEGFR2 internalization and degradation following endosome-trans-Golgi network trafficking. Angiogenesis 2013; 16:625-637.
17. Van Belle E., Rivard A, Chen D., Silver M, Bunting S, Ferrara N et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96:2667-2674.
18. Jang JJ, Ho HK, Kwan H.H., Fajardo LF, Cooke JP Angiogenesis is impaired by hyperchol-esterolemia: role of asymmetric dimethylarginine. Circulation 2000; 102:1414-1419.
19. Tirziu D, Moodie KL, Zhuang Z.W., Singer K., Helisch A, Dunn JF et al. Delayed arteriogen-esis in hypercholesterolemic mice. Circulation 2005; 112:2501-2509.
20. Zechariah A, El Ali A, Hagemann N, Jin F., Doeppner TR, Helfrich I et al. Hyperlipidemia attenuates vascular endothelial growth factor-induced angiogenesis, impairs cerebral blood flow, and disturbs stroke recovery via decreased pericyte coverage of brain endo-thelial cells. Arterioscler Thromb Vasc Biol 2013; 33:1561-1567.
21. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28:1950-1959.
22. Zheng H, Fu G, Dai T., Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3 K/Akt/e NOS signal transduction pathway. J Cardiovasc Pharmacol 2007; 50:274-280.
23. Salvucci O, Yao L, Villalba S., Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002; 99:2703-2711.
24. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115:5102-5110.
25. Lougheed M, Steinbrecher UP Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation. J Biol Chem 1996; 271:11798-11805.
26. Zheng K, Li HY, Su X.L., Wang XY, Tian T, Li F et al. Chemokinereceptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29:31.
27. Marchese A, Benovic JL Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 2001; 276:45509-45512.
28. Slagsvold T, Marchese A, Brech A., Stenmark H. CISK attenuates degradation of the che-mokine receptor CXCR4 via the ubiquitin ligase AIP4. EMBO J 2006; 25:3738-3749.
29. Goldstein JL, Brown MS The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-438.
30. Khusal R, Da Costa Dias B, Moodley K, Penny C, Reusch U, Knackmuss S et al. In vitro inhibition of angiogenesis by antibodies directed against the 37 k Da/67 k Da laminin receptor. PLo S ONE 2013; 8:e58888.
31. Zhu Y, Liao H, Xie X., Yuan Y, Lee TS, Wang N et al. Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovasc Res 2005; 68:425-432.
32. Bikfalvi A, Sauzeau C, Moukadiri H., Maclouf J, Busso N, Bryckaert M et al. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endo-thelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol 1991; 149:50-59.
33. Rey M, Valenzuela-Fernández A, Urzainqui A, Yáñez- Mó M, Pérez-Martínez M, Penela P et al. Myosin IIA is involved in the endocytosis of CXCR4 induced by SDF-1a. J Cell Sci 2007; 120:1126-1133.
34. Gomes AL, Carvalho T, Serpa J., Torre C, Dias S. Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis. Blood 2010; 115: 3886-3894.
35. Chen CH, Jiang W, Via D.P., Luo S., Li TR, Lee YT et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation bysuppressing basic fibroblast growth factorexpres-sion. Circulation 2000; 101:171-177.
36. Chang PY, Luo S, Jiang T., Lee YT, Lu SC, Henry PD et al. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholi-pids. Circulation 2001; 104:588-593.
37. Chavakis E, Dernbach E, Hermann C., Mondorf UF, Zeiher AM, Dimmeler S. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation 2001; 103:2102-2107.
38. Hamed S, Brenner B, Abassi Z., Aharon A, Daoud D, Roguin A. Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res 2010; 126:166-174.